Noema Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Noema Pharma's estimated annual revenue is currently $5.4M per year.
- Noema Pharma's estimated revenue per employee is $155,000
Employee Data
- Noema Pharma has 35 Employees.
- Noema Pharma grew their employee count by 9% last year.
Noema Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director Clinical Operations | Reveal Email/Phone |
Noema Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Noema Pharma?
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema's research and development is focused on understanding and meeting patient needs using our novel therapies.
keywords:N/A
N/A
Total Funding
35
Number of Employees
$5.4M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Noema Pharma News
2022-04-13 - PDE10A Inhibition in Tourette Syndrome
In 2021, Noema Pharma in-licensed the PDE10A inhibitor NOE-105 from Roche12,13 for a clinical study of this drug candidate in reducing the...
2022-03-22 - Noema Pharma to Attend and Present at Stifel 2022 CNS Days
BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market...
Other Companies in Basel
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.3M | 36 | 6% | N/A |
#2 | $7M | 40 | -30% | N/A |
#3 | N/A | 43 | 8% | N/A |
#4 | $5.2M | 45 | 18% | N/A |
#5 | $11.3M | 45 | 88% | N/A |